Highlights

• Brett Sandercock has been appointed as independent Non-Executive Director of 4DMedical, effective 16 November 2026.

• Sandercock served as Chief Financial Officer of global respiratory technology company ResMed (NYSE/ASX: RMD) for 20 years, until his retirement in May 2026.

• He will chair the Audit and Risk Committee and also serve on the Remuneration and Nomination Committee.

• 4DMedical is commercialising its XV Technology platform for respiratory imaging and functional analysis, delivered through a SaaS model to hospitals and healthcare providers.

4DMedical Limited (ASX:4DX), a global medical technology company developing advanced respiratory imaging and artificial intelligence solutions, has appointed Brett Sandercock as an independent Non-Executive Director. Sandercock brings more than three decades of finance Leadership in the global healthcare technology sector, most prominently through two decades as Chief Financial Officer of ResMed, one of Australia's most internationally recognised medical device companies. The appointment is considered by the board to add material depth in financial oversight, governance and healthcare Capital Markets experience at a stage in 4DMedical's development when these capabilities are considered particularly relevant.

Background and Expertise of the Incoming Director

Brett Sandercock's career in healthcare technology finance spans more than thirty years. He joined ResMed in a finance and treasury capacity before ascending to the role of CFO in 2006, a position he held for approximately twenty years until his retirement in May 2026. During that tenure, ResMed grew substantially through international expansion, acquisitions and capital allocation decisions across a highly competitive global respiratory device market. Sandercock continues to advise ResMed in a special advisory capacity.

Prior to his ResMed career, he held finance, treasury and audit roles at a range of organisations including the Saint-Gobain group, Healthcare of Australia and PwC. His educational and professional credentials include a Bachelor of Economics from Macquarie University and membership of Chartered Accountants Australia and New Zealand.

Board Rationale and Strategic Fit

4DMedical's Managing Director and CEO pointed specifically to Sandercock's experience of taking an Australian respiratory technology company and building it into a global Market Leader as being directly relevant to decisions the company faces. These include US market expansion, navigating reimbursement pathways, completing strategic acquisitions and maintaining disciplined capital allocation. The reference to ResMed's growth journey is a pointed one, given that 4DMedical's own CT:VQ technology is being scaled into the US hospital market and that the company completed two acquisitions in recent years to broaden its software portfolio.

Sandercock's appointment as Chair of the Audit and Risk Committee reflects the board's assessment that his depth of experience in financial oversight, audit engagement and governance is well suited to overseeing the company's financial reporting and risk management processes at this stage of its commercialisation phase.

4DMedical's Technology Platform and Commercial Progress

4DMedical's core offering is XV Technology, a platform that transforms standard clinical scans into functional insights about lung ventilation, enabling physicians to detect, diagnose and monitor respiratory disease with greater precision than conventional imaging. The company's software portfolio includes FDA-cleared products for lung ventilation analysis and a newer combined ventilation-and-perfusion solution, CT:VQ, which the company has described as targeting a step-change in cardiothoracic imaging.

The platform is delivered through a Software-as-a-Service model, allowing 4DMedical to integrate its tools into existing hospital imaging infrastructure without requiring the installation of proprietary hardware. The company has broadened its AI capabilities through the Acquisition of Imbio in 2023 and contextflow in 2026, adding quantitative lung analysis and AI-driven imaging workflow tools to its portfolio. The combined offering positions 4DMedical as a software layer that can extend the diagnostic value of existing hospital scanning equipment.

Key Takeaways

• 4DMedical has appointed Brett Sandercock, former CFO of ResMed, as an independent Non-Executive Director to chair the Audit and Risk Committee.

• Sandercock brings over thirty years of healthcare technology finance experience, including twenty years overseeing the financial operations of a globally operating medical device company.

• The appointment is framed as particularly relevant to 4DMedical's priorities of US market expansion, capital allocation and financial governance.

• 4DMedical's XV Technology platform, delivered via SaaS, provides functional respiratory imaging analysis and is being scaled into hospital markets in the US and Europe.